The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,244,790 in first-year total cost, median $1,244,790.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-E (10)]1
Most frequent institutions
- CIRCUMVENT PHARMACEUTICALS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease2R44NS120360-03 | CHELSKY, DANIELSTEINER, ROBERT DAVIDWILEY, DEVIN THOMAS | CIRCUMVENT PHARMACEUTICALS, INC., CA | $1,244,790 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.